Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed - 15/08/19
![](/templates/common/images/mail.png)
Abbreviations used : IL, PASI, sPGA
Funding sources: This study received funding from Ortho Dermatologics. |
|
Conflicts of interest: Dr Kimmel participated on an advisory board for Ortho Dermatologics, October 2018. Dr Chima is a consultant for Leo Pharma. Dr Bagel is an investigator, speaker, or advisory board for LEO, Abbvie, Amgen, Eli-Lilly, Novartis, Celgene, Janssen, Boehringer Ingelheim, BMS, and UCB. Dr Lebwohl receives research funds from Abbvie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Corrona, Inc, Eli Lilly, Foundation for Research & Education in Dermatology, Incyte, Janssen Research & Development, LLC,Kadmon Corp, LLC, Leo Pharmaceuticals, MedImmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm, UCB, Inc, and ViDac and is a consultant for Allergan, Almirall, Arcutis Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Leo Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, and Verrica. Drs H. Kim, Bares, and S. Kim, and Christopher J. Yao, and Giselle Singer have no conflicts of interest to declare. |
Vol 81 - N° 3
P. 857-859 - septembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?